{"id":"W3199611447","doi":"10.1002/cam4.4260","title":"Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Astellas Pharma; Eisai; NuCana; Pfizer; Incyte; Mersana Therapeutics; Syndax Pharmaceuticals; National Institute for Health and Care Research; Clovis Oncology; U.S. Department of Defense; National Comprehensive Cancer Network; Ovarian Cancer Research Fund; Gateway Foundation; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Amgen; National Ovarian Cancer Coalition; National Institutes of Health; Regeneron Pharmaceuticals; PharmaMar; Yale University; Sanofi; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Bristol-Myers Squibb; Ovarian Cancer Research Fund Alliance; Ipsen; Array BioPharma","keywords":"Medicine; Internal medicine; Placebo; Regimen; Population; Chemotherapy; Chemotherapy regimen; Gastroenterology; Oncology; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075319,0.0002950274,0.001105846,0.0001449844,0.00008983628,0.000006618989,0.00006617355,0.00005448478,0.00006136624],"category_scores_gemma":[0.003705974,0.0001633905,0.00007613633,0.0003180533,0.0004116493,0.00002553115,0.00002486706,0.0001266504,4.932982e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005095351,"about_ca_system_score_gemma":0.0007591287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001122758,"about_ca_topic_score_gemma":0.000193176,"domain_scores_codex":[0.9978073,0.0005274785,0.000554691,0.0005233472,0.0003092597,0.0002778818],"domain_scores_gemma":[0.9934857,0.005063171,0.0002181346,0.0006169801,0.0001771658,0.0004388848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.981547,0.000721073,0.0003002266,0.0003440349,0.000142031,0.0001657683,0.001461987,0.00003804708,0.004230492,0.00009850866,0.001757012,0.00919382],"study_design_scores_gemma":[0.9517339,0.01643719,0.001352021,0.006059452,0.0006756755,0.00001663196,0.0001201526,0.0008903771,0.006373586,0.00003729193,0.01613117,0.0001725317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9246161,0.007491591,0.001034356,0.05674856,0.0002832301,0.009574566,0.0001604229,0.00002035422,0.00007082582],"genre_scores_gemma":[0.9896182,0.001292272,0.0003378632,0.003551875,0.0003764381,0.00418873,0.000102961,0.00004440891,0.0004872852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06500208,"threshold_uncertainty_score":0.6662869,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02721668678693314,"score_gpt":0.3441977582989541,"score_spread":0.316981071512021,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}